anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Bisphosphonates have been associated with a decreased risk of revision surgery after total joint arthroplasty of the hip or knee (TJA) because of their effects on decreased periprosthetic bone loss and prosthetic migration. However, the results in the early literature are inconsistent, and the influence of bisphosphonates on associated complications and subsequent TJA remains unknown. This study investigated the association between the use of bisphosphonates and the risk of adverse outcomes after primary TJA. This matched cohort study utilized the National Health Insurance Research Database in Taiwan to identify patients who underwent primary TJA over a 15-year period (January 2000-December 2015 inclusive). Study participants were further categorized into two groups, bisphosphonate users and nonusers, using propensity score matching. The Kaplan-Meier curve analysis and adjusted hazard ratios (aHRs) of revision surgery, adverse outcomes of primary surgery and subsequent TJA were calculated using Cox regression analysis. This study analyzed data from 6485 patients who underwent total hip arthroplasty (THA) and 20,920 patients who underwent total knee arthroplasty (TKA). The risk of revision hip and knee arthroplasty was significantly lower in the bisphosphonate users than in the nonusers (aHR, 0.54 and 0.53, respectively). Furthermore, the risk of a subsequent total joint arthroplasty, adverse events and all-cause mortality were also significantly reduced in the bisphosphonate users. This study, involving a large cohort of patients who underwent primary arthroplasties, revealed that bisphosphonate treatment may potentially reduce the risk of revision surgery and associated adverse outcomes. Furthermore, the use of bisphosphonates after TJA is also associated with a reduced need for subsequent arthroplasty.Research Registration Unique Identifying Number (UIN): ClinicalTrials.gov Identifier-NCT05623540 ( https://clinicaltrials.gov/show/NCT05623540 ).
The invention relates to a bullfrog skin active peptide, a gene and application thereof in pharmacy. The bullfrog skin active peptide is obtained by screening a constructed bullfrog skin cDNA library, and is a single-chain polypeptide coded by a bullfrog skin active peptide gene. The molecular weight is 3,144.8 Dalton; the isoelectric point is 10.16; and the complete-sequence primary structure of polypeptide is Met Met Arg Val Met Arg Arg Lys Thr Lys Val IIe Trp Glu Arg Arg Asp Phe IIe Gly Leu Tyr Ser IIe Asp (MMRVMRRKTKVIWEKKDFIGLYSID). The gene of the coded bullfrog skin active peptide consists of 369 nucleotides, wherein the coded bullfrog skin active peptide is nucleotides at positions 97 to 171. The synthetic bullfrog skin active peptide has obvious effect of inhibiting bacterial growth, can be applied to the preparation of medicaments for treating pathogenic microbial infection diseases, and has the function of clearing free radicals. The bullfrog skin active peptide has the characteristics of low molecular weight, simple synthesis, strong antibacterial activity, oxidation resistance and the like.
Diabetic nephropathy (DN) is a globally widespread complication of diabetes mellitus (DM). Research indicates that pioglitazone and linagliptin mitigate the risk of DN by reducing inflammation, oxidative stress, and fibrosis. The role of tamsulosin in DN is less studied, but it may contribute to reducing oxidative stress and inflammatory responses. The protective effects of combining pioglitazone, linagliptin, and tamsulosin on the kidneys have scarcely been investigated. This study examines the individual and combined effects of these drugs on DN in Wistar rats. Diabetic rats were treated with tamsulosin, pioglitazone, and linagliptin for six weeks. We assessed food and water intake, estimated glomerular filtration rate (eGFR), histological markers, urea, creatinine, glucose, NF-κB, IL-1, IL-10, TGF-β, and Col-IV using immunofluorescence and qPCR. The DN group exhibited hyperglycaemia, reduced eGFR, and tissue damage. Tamsulosin and linagliptin improved eGFR, decreased urinary glucose, and repaired tissue damage. Pioglitazone and its combinations restored serum and urinary markers and reduced tissue damage. Linagliptin lowered serum creatinine and tissue injury. In conclusion, tamsulosin, linagliptin, and pioglitazone demonstrated renoprotective effects in DN.
Static stretching exercises (12 sessions, twice a week, for six weeks, 15 minutes a day, for 2 sets of 40 seconds each side). Assessments and reassessments will be carried out in the first, fourth and sixth week.
Falls in the elderly can have devastating consequences. The ability to maintain stability and balance is critical for functional independence, mobility, and avoidance of falls in activities of daily living. An impaired balance is associated with an increased risk of falls and causes a higher mortality rate among older adults. Balance impairment is independently associated with falls in patients with Chronic obstructive pulmonary disease. Well-known risk factors for falls in individuals with Chronic obstructive pulmonary disease include advanced age, increased comorbidities, dyspnea, physical inactivity, muscle weakness, fear and decreased balance confidence, as well as lower extremity muscle weakness. It has been reported that there are functional deficiencies, lack of performance and postural control. According to the results of a recent study, it was found that Chronic obstructive pulmonary disease is in the second place after osteoarthritis in chronic conditions where the prevalence of falls is highest. The prevalence of falls in individuals with Chronic obstructive pulmonary disease is estimated to range from 25% to 46%.
500 participants between the ages of 18-40 who will be undergoing surgery requiring general anesthetic will be recruited for this study. This study will use the Isolated Forearm Test (IFT) to identify patients at risk of anesthesia awareness. In the IFT, induction of anesthesia is followed by inflation of a cuff on the dominant arm before neuromuscular blockade (paralysis) is induced. The cuff prevents paralysis of the hand allowing the patient to communicate to an observer through predefined hand movements, typically following a command like: "Mrs. Jones, if you can hear me, squeeze my hand". Participants will thus be asked to follow a series of commands intraoperatively to assess awareness.

Routinely recorded clinical data will be collected to frame the observations about IFT responsiveness, and non-invasive EEG data will also be collected to provide information about the "brain state" of the patients. Patient reported confusion and objectively measured confusion using the Nurse Based Delirium Screening Tool (NuDesc) will be collected post operatively. Finally, participants will be contacted 24 hours and 7 days following their operation to complete an anesthesia satisfaction questionnaire.
PURPOSE:To obtain a bathing agent composition having excellent body-warming effect and rust-proofing effect and usable without damaging the bath boiler and bathtub by using a chloride as a main component and adding compounds selected from sodium carbonate, disodium succinate, etc. CONSTITUTION:The objective composition is produced by using a chloride (e.g. NaCl, KCl, MgCl2 or CaCl2) as a main component and adding two or more compounds selected from Na2CO3, disodium succinate, aluminum sulfate and NaHCO3. The amount of the compounds to be added to the chloride is 0.4-8.0 pts.wt. (especially 0.5-4.0 pts.wt.) based on 1 pt.wt. of the chloride. The rusting of the bath boiler and bathtub caused by the chlorine ion generated by the use of the chloride can be suppressed by the addition of the above compounds.
This is a prospective study on ten children using Cyclosporin-A (CSA) microemulsion to treat idiopathic nephrotic syndrome (INS), with normal renal function, who achieved complete remission with CSA. The objective is to compare the pharmacokinetic (PK) parameters of CSA in INS during remission and relapse of the disease. The PK profile of CSA was evaluated with the 12-hour area under the time-concentration curve (AUC0-12) using seven time-point samples. This procedure was done on each patient during remission and relapse with the same CSA dose in mg/kg/day. The AUC0-12 was calculated by trapezoidal rule. All PK parameters and the resumed 4-hour area under the time-concentration curve (AUC0-4) were correlated with AUC0-12. This study is very important because the cyclosporin is a nephrotoxic drug with narrow therapeutic window.
Aging leads to a decrease in muscle function, mass, and strength in skeletal muscle of animals and humans. The transcriptome identified activation of the JAK/STAT pathway, a pathway that is associated with skeletal muscle atrophy, and endurance training has a significant effect on improving sarcopenia; however, the exact mechanism still requires further study. We investigated the effect of endurance training on sarcopenia. Six-month-old male SAMR1 mice were used as a young control group (group C), and the same month-old male SAMP8 mice were divided into an exercise group (group E) and a model group (group M). A 3-month running exercise intervention was performed on group E, and the other two groups were kept normally. Aging caused significant signs of sarcopenia in the SAMP8 mice, and endurance training effectively improved muscle function, muscle mass, and muscle strength in the SAMP8 mice. The expression of JAK2/STAT3 pathway factor was decreased in group E compared with group M, and the expression of SOCS3, the target gene of STAT3, and NR1D1, an atrophy-related factor, was significantly increased. Endurance training significantly improved the phenotypes associated with sarcopenia, and the JAK2/STAT3 pathway is a possible mechanism for the improvement of sarcopenia by endurance training, while NR1D1 may be its potential target. Keywords: Sarcopenia, Endurance training, Janus kinase 2/signal transducer and activator of transcription 3 (JAK2/STAT3), Nuclear receptor subfamily 1, group D member 1 (Nr1d1).
While most adults confronted with the death of a loved one manage to grieve, about 10-20% of individuals develop complicated grief, characterized by persistent distress and impaired social skills, or pathological grief, defined by the onset or decompensation of a psychiatric disorder. Little is known about the biological causes of these grief complications. Recent work suggests that oxytocin, a major neuroendocrine hormone regulating many neurocognitive mechanisms, may be involved in this process. Oxytocin is widely studied and well known for its impact on the mother-child bond and hormonal and brain systems related to attachment and social interactions. In this article, we propose a neurocognitive model of grief complications based on existing data on the role of oxytocin in interpersonal attachment and its impact on brain activity. We suggest that complicated grief is associated with dysfunctional cerebral oxytocinergic signaling and persistent hyperactivation of the nucleus accumbens. This mechanism is involved in limiting the reduction of interpersonal attachment to the deceased during acute phases and in searching for new interpersonal relationships during the recovery phase. We show how the exploration of cerebral oxytocinergic signaling would improve the understanding of physiological grief mechanisms in the general population and could allow the development of new therapeutic perspectives against the complications of grief.
PURPOSE: To obtain a protectant containing urokinase(UK) having actions on proliferation of a vascular endothelial cell or its precursor as an active ingredient. CONSTITUTION: This protectant for a vascular endothelial cell contains UK or its precursor as an active ingredient. The UK may be a highly purified one and the UK derived from urine, renal cell culture or genetic engineering, etc., is applied. The UK precursor having, e.g. 50,000-55,000 molecular weight, a single-stranded peptide structure and 411 constituent amino acids is cited as the UK precursor. The UK precursor is preferably a highly purified product and, e.g. about 300U (units)/mg protein is cited. Furthermore, the daily dose of the UK is about 1-1,000,000IU for an adult and about 1-10 days are exemplified as the administration period. The daily dose of the UK precursor is about 1500-20000U for an adult and about 1-10 days are exemplified as the administration period.  The intraarterial infusion, intravenous injection, sustained drip infusion, local administration, etc., are exemplified as the administration.
Three episodes of overdose occurred in the open-label trials performed in support of registration. Eight cases of overdose with tetrabenazine have been reported in the literature. The dose of tetrabenazine in these patients ranged from 100 mg to 1 g. Adverse reactions associated with tetrabenazine overdose include acute dystonia, oculogyric crisis, nausea and vomiting, sweating, sedation, hypotension, confusion, diarrhea, hallucinations, rubor, and tremor.   
  
Treatment should consist of those general measures employed in the management of overdosage with any CNS-active drug. General supportive and symptomatic measures are recommended. Cardiac rhythm and vital signs should be monitored. In managing overdosage, the possibility of multiple drug involvement should always be considered. The physician should consider contacting a poison control center on the treatment of any overdose.
PURPOSE OF THE REVIEW: Breathlessness may evoke existential threat but may also affect the person with serious illness or their caregiver/s in other important ways which can be considered 'existential'. This review explores existential aspects of breathlessness in people with serious illness and presents recent studies of assessment and management of associated distress and suffering.
RECENT FINDINGS: Both existential distress and breathlessness are multidimensional and include a range of constructs, many of which have behavioural consequences. Existential distress tracks closely with distressing breathing potentially due to shared underlying neurobiological processing. Paradoxically 'contagious' and isolating effects of breathlessness and related distress have been recently highlighted. Approaches to screening and assessment vary. Preliminary studies have investigated novel approaches to breathing-related anxiety and existential distress.
SUMMARY: Studies with existential constructs as outcome measures in people with breathlessness are scarce. Interventions for existential distress developed for those with malignant disease may be beneficial for those with non-malignant conditions, but adaptations may be required. Recently proposed taxonomies of existential distress/concerns may guide assessment and direct novel therapeutic interventions in people living with serious illness and breathlessness-related distress. Neglecting existential aspects of breathlessness represents a missed opportunity to support holistic well-being in people with serious illness.
The present invention provides a dermatologic or cosmetic composition, including a liquid fatty phase, and, as surfactant and thickener for the liquid fatty phase, particles of a crosslinked elastomeric solid polyorganosiloxane containing at least one oxyalkylenated group. Another embodiment of the invention relates to methods of using particles of a crosslinked elastomeric solid polyorganosiloxane containing at least one oxyethylenated group. The present invention is especially suitable for a care or make-up composition for human skin and lips, and overcomes the various drawbacks in known compositions. In particular, the present invention provides a composition for human skin and lips that results in a film that does not transfer; that has better cosmetic properties, freshness and matte-effect properties; and that is desirably longer-lasting than conventional “transfer-resistant” products, in particular the properties of slipperiness, of not feeling taut and of not drying out the lips, of having good staying power over time, particularly with respect to the color (no color change over time) and of not migrating, in particular into the folds of the skin. The invention applies not only to make-up products for human lips and skin, but also to care and/or treatment products for human lips and skin. The composition of the invention can also be applied to the scalp.
It is a prospective randomized controlled study. It is designed to estimate and compare the analgesic effect of single shot serratus anterior plane block in pediatric patients undergoing thoracic surgeries with fentanyl infusion versus fentanyl infusion alone as the control group. Our primary outcome will be the total dose of intra-operative fentanyl boluses.

Randomization will be achieved by using an online random number generator. Blindness will be achieved by patient codes which will be placed into sequentially numbered sealed opaque envelopes by a research assistant who is not involved in the study. A physician not involved in patient management will be responsible for opening the envelope and give the instructions contained within each envelope to the anaesthesiologist who is expert in doing the serratus anterior plane block in patients included within the block group. This expert anaesthesiologist will not be involved in collecting data but another anaesthesia doctor will be responsible for patient management and collecting the intraoperative and postoperative data.
NSAIDs, including diclofenac, a component of ARTHROTEC, can cause serious skin adverse reactions such as exfoliative dermatitis, Stevens-Johnson Syndrome (SJS), and toxic epidermal necrolysis (TEN), which can be fatal. NSAIDs can also cause fixed drug eruption (FDE). FDE may present as a more severe variant known as generalized bullous fixed drug eruption (GBFDE), which can be life-threatening. These serious events may occur without warning. Inform patients about the signs and symptoms of serious skin reactions, and to discontinue the use of ARTHROTEC at the first appearance of skin rash or any other sign of hypersensitivity. ARTHROTEC is contraindicated in patients with previous serious skin reactions to NSAIDs [see Contraindications (4)].
PURPOSE:To obtain a pigment which does not have any pearly luster and has hiding power, good adhesion to the skin and good spreadability, by heating a mixture of mica and titanyl sulfate, hydrolyzing titanyl sulfate at a b.p. and firing the resulting solid product. CONSTITUTION:Mica or an aq. dispersion thereof (a) is mixed with titanyl sulfate (total sulfuric acid/total TiO2: 1.5-5.5) or an aq. soln. thereof (b) with stirring in such a proportion as to give a mixture wherein the concn. of titanyl sulfate is 50g/l or higher and the weight ratio of mica to titanyl sulfate is 0.01-4. The mixture is heated to a b.p. and hydrolyzed at the b.p. to deposit hydrated titanium dioxide on the surface of mica. In some cases, neutralization with an alkali is conducted and the resulting solid product is separated and fired to obtain the desired pigment. When the pigment is combined with a spherical powder, a make-up cosmetic which can be smoothly spread and has good touch can be obtd.
PURPOSE:To provide an antitumor agent containing a monoacetoacetin as an active component, effective as a remedy for cancer and capable of establishing an ideal nutrition of a cancerous body. CONSTITUTION:The objective agent can be prepared by using a monoacetoacetin as an active component, compounding conventional additives such as diluent, dissolution assistant, buffering agent, preservative, colorant and perfumery and preparing to a drug form by conventional process. It can be used in the form of a transfusion suitable for the administration through the vein such as peripheral vein or central vein, a liquid suitable for the transintestinal administration (e.g., administration through the canal or mouth), etc. The administration rate as a transfusion is 100-4,000ml per day for adult. Monoacetoacetin is a known compound composed of glycerol and acetoacetic acid and is capable of suppressing the proliferation of tumor cell while keeping the nutrition state of the living body. The life of a cancerous body can be prolonged without causing the lowering of the immunological competence or causing cachexia, since the cancerous body is not subjected to fatigue or malnutrition.
A reminder letter as above is sent first. If a woman does not call in to schedule a mammogram within 2 weeks, a second letter is sent along with a mammography educational booklet. The second letter also reiterates a reminder that her PCP recommends screening every 1-2 years, and offers a special number to call to schedule. If a woman does not schedule within 8-10 days, a counselor will call. The protocol script included tailored barriers counseling, correction of misinformation and motivational interviewing. Repeat "booster" letters will be sent and repeat counselors calls made in subsequent years to those failing to get a mammogram. techniques. Average calls last 20-30 minutes.
PCT No. PCT/ES92/00032 Sec. 371 Date Jan. 27, 1993 Sec. 102(e) Date Jan. 27, 1993 PCT Filed Mar. 26, 1992 PCT Pub. No. WO92/17589 PCT Pub. Date Oct. 15, 1992.Method for the production of a subunit vaccine against porcine parvovirus (PPV). The method is comprised of a first step wherein a recombinant protein VP2 of PPV is obtained by using the replication of a recombinant baculovirus wherein the gene corresponding to VP2 has been previously inserted in cells of a permissive host. The protein VP2 obtained in this invention has the capacity of forming empty chimeric capsids with high immunogenicity and can be provided as a vaccine formulation for protecting pigs against PPV infection. The recombinant baculovirus AcMNPV.pPPVEx8 expresses the VP2 of PPV in conditions making possible the formation of pseudo-viral capsids.
Adverse reactions have occurred with the anti-infective components of neomycin and polymyxin B sulfates and bacitracin zinc ophthalmic ointment. The exact incidence is not known. Reactions occurring most often are allergic sensitization reactions including itching, swelling, and conjunctival erythema (see WARNINGS). More serious hypersensitivity reactions, including anaphylaxis, have been reported rarely.

Local irritation on instillation has also been reported.

To report SUSPECTED ADVERSE REACTIONS, contact Rising Pharma Holdings, Inc. at (1-844-874-7464) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Barcelona Clinic Liver Cancer (BCLC) staging system is the most widely used stage classification for HCC management. For patients with intermediate HCC, palliative treatment transarterial chemoembolization (TACE) was recommended as first choice treatment. However, this recommendation remains controversial. The advice for diagnosis and treatment of HCC from former Chinese Ministry of Health indicated that BCLC may not be suitable in China as most HCC patients were found in intermediate or advanced stage. In recent years, more and more studies declared surgical resection as a better choice for HCC patients in BCLC stage B. However, lack of randomization, small sample size and lack of prospective studies limit the strength of evidence.

To solve this dilemma, a prospective randomized control study was performed to compare the efficacy (1-, 2-, 3-year survival) between surgical resection group and TACE plus radiofrequency ablation group in HCC patients in intermediate stage. This study will provide powerful evidence regarding the better treatment option for HCC patients in BCLC B stage, which will benefit the treatment efficacy of HCC patients in BCLC B stage.